REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Seven-membered Consisting Of Two Nitrogens And Five Carbon Atoms > Polycyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos Polycyclo Ring System Having The Seven-membered Hetero Ring As One Of The CyclosPolycyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027142 - Diazepinoquinolines, synthesis thereof, and intermediates thereto The present invention relates to methods for synthesizing compounds useful as 5HT2C agonists or partial agonists, derivatives thereof, and to intermediates thereto. ... 09/28/06 - 20060217370 - Compounds useful for the treatment and prevention of pain and screening methods therefor and to a method of treatment or prevention of pain using the above compounds. ... 08/17/06 - 20060183737 - Treatment of t-helper cell type 2-mediated immune diseases by retinoid antagonists Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases. ... 07/27/06 - 20060166969 - Ampa antagonists for the treatment of dizziness, including vertigo and meniere's disorder prodrugs, tautomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of the foregoing, for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of dizziness, including vertigo and Menière's disorder. ... 06/15/06 - 20060128691 - Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives and pharmaceutically acceptable acid addition salts thereof. This class of compounds have high affinity and selectivity for GABA A α5 receptor binding sites. Thus, the invention also relates to methods of enhancing cognition and treating cognitive disorders like Alzheimer's disease. ... 04/20/06 - 20060084642 - Substituted imidazol[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives R3 is hydrogen, methyl or aryl; R is lower alkyl, cycloalkyl or aryl; and pharmaceutically acceptable acid addition salts thereof. Such compounds have a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders, anxiety, ... 04/13/06 - 20060079507 - Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH2)nO-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most ... 11/17/05 - 20050256108 - Spiroazacyclic compounds as monoamine receptor modulators The present invention relates to spiroazacyclic compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment ... 11/10/05 - 20050250763 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions wherein A, X and R1 to R3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these ... 10/13/05 - 20050227967 - Treatment of t-helper cell type 2-mediated immune diseases by retinoid antagonists Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases. ... ### FreshPatents.com Support |